COVID-19大流行,由SARS-CoV-2引起的,在全球范围内提出了重大的健康挑战。虽然与成年人相比,儿童通常经历较少严重的疾病,肺炎仍然是一个很大的风险,特别是对于五岁以下的人。本研究调查了在泰国接受favipiravir治疗的儿童COVID-19肺炎患者的临床特征和治疗结果,旨在确定肺炎的相关因素。对在斯利那加林德医院因COVID-19住院的1个月至18岁的儿科患者进行了回顾性研究,孔敬大学,从2020年1月13日至2021年11月15日。人口统计数据,临床症状,治疗,并收集了结果,并采用logistic回归分析确定与肺炎相关的因素.在349名住院儿童中,中位年龄为8岁,51.9%是男性。症状包括发烧(100%),咳嗽(74.2%),和皮疹(24.9%)。54.7%的儿童被诊断出COVID-19肺炎。Favipiravir作为标准治疗,表现出轻微的不良反应,包括皮疹(4.3%)和恶心(2.8%)。单核细胞增多与COVID-19肺炎显著相关(aOR30.85,95%CI:9.03-105.41,p<0.001),ROC曲线面积为0.77(95%CI:0.71-0.83)。儿科COVID-19患者通常表现为轻度至中度症状,肺炎在大流行的早期阶段很常见。单核细胞增多是与COVID-19肺炎相关的重要因素。Favipiravir表现出轻微的不良反应。需要进一步的研究来验证这些发现在大流行的不同背景和阶段。
The COVID-19 pandemic, caused by SARS-CoV-2, has posed significant health challenges worldwide. While children generally experience less severe illness compared to adults, pneumonia remains a substantial risk, particularly for those under five years old. This study examines the clinical characteristics and treatment outcomes of pediatric COVID-19 pneumonia patients treated with
favipiravir in Thailand, aiming to identify associated factors for pneumonia. A retrospective review was performed on pediatric patients aged 1 month to 18 years hospitalized with COVID-19 at Srinagarind Hospital, Khon Kaen University, from 13 January 2020 to 15 November 2021. Data on demographics, clinical symptoms, treatment, and outcomes were collected, and logistic regression analysis was used to identify factors associated with pneumonia. Among 349 hospitalized children, the median age was 8 years, with 51.9% being male. Symptoms included a fever (100%), a cough (74.2%), and a rash (24.9%). COVID-19 pneumonia was diagnosed in 54.7% of the children.
Favipiravir was administered as the standard treatment, showing mild adverse effects, including a rash (4.3%) and nausea (2.8%). Monocytosis was significantly associated with COVID-19 pneumonia (aOR 30.85, 95% CI: 9.03-105.41, p < 0.001), with an ROC curve area of 0.77 (95% CI: 0.71-0.83). Pediatric COVID-19 patients typically exhibit mild-to-moderate symptoms, with pneumonia being common in the early pandemic phase. Monocytosis is a significant factor associated with COVID-19 pneumonia.
Favipiravir demonstrated mild adverse effects. Further studies are needed to validate these findings across different settings and phases of the pandemic.